RBC bumps Wells Fargo’s rating to 'outperform' after stock decline

[
RBC bumps Wells Fargo’s rating to 'outperform' after stock decline
[og_img]
https://www.investing.com/news/stock-market-news/rbc-bumps-wells-fargos-rating-to-outperform-after-stock-decline-3927330

Investing.com

Hackers are hijacking your typos to plant stealthy malware – and even the best antivirus might not catch it

iOS 19: the 5 upgrades I’m really hoping for at WWDC 2025

Gaming keyboards seem to be getting better and better – but there are still some features I wish they had

Ricoh unveils the Theta A1, its most rugged 360 camera yet

Ex-Israeli Intelligence Official: Shockwaves of Trump’s “Take Over Gaza” Heard, Felt Across Region

What UK political parties are promising in the 2019 general election

Otto Warmbier’s parents want North Korea to suffer for their son’s death

Could a ‘youthquake’ cause Boris Johnson to lose the general election?

Which Celebrity Styles Americans Copy Most in 2025: New Study

New ‘Westworld’ trailer introduces us to another dystopian tech company

What’s the point of ‘Charlie’s Angels’ without Sam Rockwell dancing?

These striking photos capture the future of human flight

How Charlie Scharf got Wells Fargo out of the penalty box

Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints

Bio-Techne at William Blair Growth Stock: Strategic Insights and Challenges

TruGolf to Paricipate in the 2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow Conference Presented by Maxim Group LLC on Wednesday, June 4th...

The YouTuber who has become one of Gen Z’s most beloved celebrities

26 last-minute holiday gifts that are still thoughtful and unique

Practicing gratitude regularly can make you less stressed and sleep better

8 things millennials wish you would just stop getting them for the holidays

RBC bumps Wells Fargo’s rating to 'outperform' after stock decline

How Charlie Scharf got Wells Fargo out of the penalty box

Ascletis Announces Phase III Trial of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne, Meets All Endpoints

Bio-Techne at William Blair Growth Stock: Strategic Insights and Challenges

TruGolf to Paricipate in the 2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow Conference Presented by Maxim Group LLC on Wednesday, June 4th...